GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track

Biocon Biologics signs licensing agreement with Yoshindo

Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics

BioMarin simplifies organizational structure to increase efficiency

The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023

Sumitovant Biopharma and Sumitomo Pharma to acquire outstanding shares of Myovant Sciences

The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.